| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C25H26N2O5 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
JW 55 is a potent, selective inhibitor of the β-catenin signaling pathway that acts by inhibiting the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). It decreases auto-PARsylation of TNKS1/2 in vitro, with IC50 values of 1.9 μM and 830 nM, respectively. It is supplied as a white to off-white solid (C25H26N2O5, MW 434.48) at 99.83% purity.
Physical & Chemical Properties
| CAS Number | 664993-53-7 |
|---|---|
| Molecular Formula | C25H26N2O5 |
| Molecular Weight | 434.48 g/mol |
| Purity | 99.83% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(C1=CC=CO1)NC2=CC=C(C(NCC3(C4=CC=C(OC)C=C4)CCOCC3)=O)C=C2 |
| Target | TNKS2, TNKS1 |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics |
| Solubility | In Vitro: DMSO: ≥ 50 mg/mL (115.08 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
TNKS2 0.83 μM (IC50) |
TNKS1 1.9 μM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 50 mg/mL (115.08 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (5.75 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (5.75 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (5.75 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
JW 55 (JW55) is a potent, selective inhibitor of the canonical Wnt pathway. In Wnt3a-induced HEK293 cells with a transiently transfected ST-Luc (SuperTop-luciferase) reporter, JW55 inhibits the signal with an IC50 value of 470 nM. JW55 is effective at 1 to 5 μM in SW480 cells and at 0.01 to 5 μM in HCT-15 cells[1].
In Vivo
In conditional Apc knockout mice, tumor development is reduced by JW 55 (100 mg/kg, orally). Axis duplication induced by XWnt8 in Xenopus embryos is reduced by JW55, as is polyposis formation induced by Tamoxifen in conditional APC mutant mice[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[1]
Seed 1,000 SW480 or RKO cells in 96-well plates. The next day, exchange the cell culture medium for solutions containing 0.1% DMSO or 10 μM JW55 for RKO cells, or 0.1% DMSO or JW55 at 10, 5, or 1 μM for SW480 cells. Prepare a minimum of 6 replicates for every sample. Incubate the plate in an IncuCyte placed inside a cell culture incubator, and capture images every second hour to monitor proliferation[1].
Animal Administration[1]
Mice[1] Inject seven 12-week old female ApcCKO/CKO/Lgr5-CreERT2 mice intraperitonally with 25 mg/kg of Tamoxifen diluted in ethanol and corn oil (ratio 1:4). Randomize the mice into 2 groups and treat with either JW55 (100 mg/kg) or vehicle (DMSO). Begin daily per oral applications the next day and continue for 3 weeks. Measure mouse body weight twice a week. Sacrifice the mice, dissect the intestines, wash in PBS, and fix in formaldehyde [10% solution (v/v) in PBS]. Stain the small intestines with 1% methylene blue prepared in 10% paraformalaldehyde (PFA)/PBS solution. Embed small ileum Swiss-rolls in paraffin, section, and stain with hematoxylin and eosin. Embed fixed colons in paraffin, section, and stain with an anti-β-catenin antibody. Quantify the number and size of intestinal lesions with the Ellipse program.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Tankyrase activity is essential for asymmetric division and chromosome segregation in oocyte meiosis. J Adv Res 2025 Jul 7:S2090-1232(25)00506-5. PMID: 40633837
A pathogenic variant of AMOT leads to isolated X-linked congenital hydrocephalus due to N-terminal truncation. J Clin Invest 2025 Sep 2;135(17):e179438. PMID: 40892511
Astragalus membranaceus (Huangqi) and Rhizoma curcumae (Ezhu) decoction suppresses colorectal cancer via downregulation of Wnt5/β-Catenin signal. Chin Med 2022 Jan 6;17(1):11. PMID: 34991661
Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl) 2019 Aug;97(8):1183-1193.
Naringenin Protected Against Blood Brain Barrier Breakdown after Ischemic Stroke through GSK-3β/ β-Catenin Pathway. Neurochem Res 2024 Nov 18;50(1):17. PMID: 39556287
